Guardant Health Grants Co-CEOs 465,413 Performance-Based Stock Units Each at Target
Bitget2026/11/03 13:20- Guardant Health granted co-CEOs Helmy Eltoukhy and AmirAli Talasaz 465,413 target performance-based restricted stock units each on November 2, 2026.
- Performance periods begin June 1, 2026; 25% runs through May 31, 2029, with 75% through May 31, 2031.
- Payouts require S&P 500-relative shareholder returns reaching the 40th percentile; target requires the 55th percentile, with 250% earned at the 90th percentile.
- Negative absolute total shareholder returns cap payouts at 100% of target; vesting generally requires continued service through performance certification.
- Three-year award shares generally face holding restrictions through May 31, 2030; restrictions cover half of five-year net after-tax shares through November 30, 2031.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
